Zimmer Biomet Holdings, Inc. (NYSE: ZBH) Stock Competitors & Peer Comparison
See ZBH's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ZBH and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ZBH | $97.89 | +0.68% | 18.9B | 11.54 | $8.48 | +0.98% |
| ABT | $110.91 | +1.08% | 191.9B | 21.29 | $5.21 | +2.26% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| SYK | $347.21 | -0.27% | 133.1B | 25.93 | $13.39 | +1.00% |
| MDT | $90.76 | +0.09% | 116.2B | 16.41 | $5.53 | +3.15% |
| BSX | $51.42 | +0.45% | 76.4B | 16.58 | $3.10 | N/A |
| EW | $93.05 | -0.65% | 53.6B | 34.46 | $2.70 | N/A |
| DXCM | $90.80 | +1.42% | 34.3B | 38.97 | $2.33 | N/A |
| RMD | $226.00 | +0.52% | 32.8B | 20.99 | $10.77 | +1.07% |
| PHG | $26.80 | -0.92% | 26.2B | 15.32 | $1.75 | +3.65% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
ZBH vs ABT Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, ABT has a market cap of 191.9B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while ABT trades at $110.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas ABT's P/E ratio is 21.29. In terms of profitability, ZBH's ROE is +0.06%, compared to ABT's ROE of +0.11%. Regarding short-term risk, ZBH is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
ZBH vs BSX-PA Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, ZBH's ROE is +0.06%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, ZBH is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check BSX-PA's competition here
Stryker Corporation (NYSE: SYK)
ZBH vs SYK Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, SYK has a market cap of 133.1B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while SYK trades at $347.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas SYK's P/E ratio is 25.93. In terms of profitability, ZBH's ROE is +0.06%, compared to SYK's ROE of +0.16%. Regarding short-term risk, ZBH is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check SYK's competition here
Medtronic plc (NYSE: MDT)
ZBH vs MDT Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, MDT has a market cap of 116.2B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while MDT trades at $90.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas MDT's P/E ratio is 16.41. In terms of profitability, ZBH's ROE is +0.06%, compared to MDT's ROE of +0.10%. Regarding short-term risk, ZBH is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check MDT's competition here
Boston Scientific Corporation (NYSE: BSX)
ZBH vs BSX Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, BSX has a market cap of 76.4B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while BSX trades at $51.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas BSX's P/E ratio is 16.58. In terms of profitability, ZBH's ROE is +0.06%, compared to BSX's ROE of +0.15%. Regarding short-term risk, ZBH is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
ZBH vs EW Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, EW has a market cap of 53.6B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while EW trades at $93.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas EW's P/E ratio is 34.46. In terms of profitability, ZBH's ROE is +0.06%, compared to EW's ROE of +0.10%. Regarding short-term risk, ZBH is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
ZBH vs DXCM Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, DXCM has a market cap of 34.3B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while DXCM trades at $90.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas DXCM's P/E ratio is 38.97. In terms of profitability, ZBH's ROE is +0.06%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, ZBH is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check DXCM's competition here
ResMed Inc. (NYSE: RMD)
ZBH vs RMD Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, RMD has a market cap of 32.8B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while RMD trades at $226.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas RMD's P/E ratio is 20.99. In terms of profitability, ZBH's ROE is +0.06%, compared to RMD's ROE of +0.24%. Regarding short-term risk, ZBH is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check RMD's competition here
Koninklijke Philips N.V. (NYSE: PHG)
ZBH vs PHG Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, PHG has a market cap of 26.2B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while PHG trades at $26.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas PHG's P/E ratio is 15.32. In terms of profitability, ZBH's ROE is +0.06%, compared to PHG's ROE of +0.10%. Regarding short-term risk, ZBH is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check PHG's competition here
Abiomed, Inc. (NASDAQ: ABMD)
ZBH vs ABMD Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas ABMD's P/E ratio is 65.36. In terms of profitability, ZBH's ROE is +0.06%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, ZBH is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
ZBH vs PEN Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, PEN has a market cap of 12.9B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while PEN trades at $326.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas PEN's P/E ratio is 85.30. In terms of profitability, ZBH's ROE is +0.06%, compared to PEN's ROE of +0.11%. Regarding short-term risk, ZBH is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
ZBH vs SWAV Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas SWAV's P/E ratio is 78.76. In terms of profitability, ZBH's ROE is +0.06%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, ZBH is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check SWAV's competition here
Smith & Nephew plc (NYSE: SNN)
ZBH vs SNN Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, SNN has a market cap of 12.5B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while SNN trades at $29.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas SNN's P/E ratio is 14.05. In terms of profitability, ZBH's ROE is +0.06%, compared to SNN's ROE of +0.12%. Regarding short-term risk, ZBH is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check SNN's competition here
Align Technology, Inc. (NASDAQ: ALGN)
ZBH vs ALGN Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, ALGN has a market cap of 12.5B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while ALGN trades at $174.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas ALGN's P/E ratio is 15.86. In terms of profitability, ZBH's ROE is +0.06%, compared to ALGN's ROE of +0.14%. Regarding short-term risk, ZBH is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check ALGN's competition here
Globus Medical, Inc. (NYSE: GMED)
ZBH vs GMED Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, GMED has a market cap of 11.6B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while GMED trades at $85.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas GMED's P/E ratio is 19.30. In terms of profitability, ZBH's ROE is +0.06%, compared to GMED's ROE of +0.12%. Regarding short-term risk, ZBH is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check GMED's competition here
Glaukos Corporation (NYSE: GKOS)
ZBH vs GKOS Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, GKOS has a market cap of 11B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while GKOS trades at $186.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas GKOS's P/E ratio is -216.86. In terms of profitability, ZBH's ROE is +0.06%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, ZBH is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check GKOS's competition here
Insulet Corp. (NASDAQ: PODD)
ZBH vs PODD Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, PODD has a market cap of 10B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while PODD trades at $145.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas PODD's P/E ratio is 24.71. In terms of profitability, ZBH's ROE is +0.06%, compared to PODD's ROE of +0.27%. Regarding short-term risk, ZBH is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check PODD's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
ZBH vs BIO Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, BIO has a market cap of 9.8B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while BIO trades at $362.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas BIO's P/E ratio is 39.04. In terms of profitability, ZBH's ROE is +0.06%, compared to BIO's ROE of +0.03%. Regarding short-term risk, ZBH is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check BIO's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
ZBH vs BIO-B Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, BIO-B has a market cap of 9.5B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while BIO-B trades at $348.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas BIO-B's P/E ratio is 103.33. In terms of profitability, ZBH's ROE is +0.06%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, ZBH is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check BIO-B's competition here
Masimo Corporation (NASDAQ: MASI)
ZBH vs MASI Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas MASI's P/E ratio is 44.43. In terms of profitability, ZBH's ROE is +0.06%, compared to MASI's ROE of +0.09%. Regarding short-term risk, ZBH is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
ZBH vs BRKR Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, BRKR has a market cap of 9B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while BRKR trades at $59.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas BRKR's P/E ratio is 29.78. In terms of profitability, ZBH's ROE is +0.06%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, ZBH is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check BRKR's competition here
Inari Medical, Inc. (NASDAQ: NARI)
ZBH vs NARI Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas NARI's P/E ratio is -59.24. In terms of profitability, ZBH's ROE is +0.06%, compared to NARI's ROE of -0.00%. Regarding short-term risk, ZBH is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check NARI's competition here
LivaNova PLC (NASDAQ: LIVN)
ZBH vs LIVN Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, LIVN has a market cap of 4.4B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while LIVN trades at $80.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas LIVN's P/E ratio is 19.19. In terms of profitability, ZBH's ROE is +0.06%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, ZBH is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check LIVN's competition here
Integer Holdings Corporation (NYSE: ITGR)
ZBH vs ITGR Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, ITGR has a market cap of 4.2B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while ITGR trades at $125.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas ITGR's P/E ratio is 19.70. In terms of profitability, ZBH's ROE is +0.06%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, ZBH is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check ITGR's competition here
Haemonetics Corporation (NYSE: HAE)
ZBH vs HAE Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, HAE has a market cap of 4.2B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while HAE trades at $91.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas HAE's P/E ratio is 18.23. In terms of profitability, ZBH's ROE is +0.06%, compared to HAE's ROE of +0.11%. Regarding short-term risk, ZBH is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check HAE's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
ZBH vs IRTC Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, IRTC has a market cap of 4.1B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while IRTC trades at $125.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas IRTC's P/E ratio is -195.86. In terms of profitability, ZBH's ROE is +0.06%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, ZBH is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
ZBH vs AXNX Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas AXNX's P/E ratio is -709.80. In terms of profitability, ZBH's ROE is +0.06%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, ZBH is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check AXNX's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
ZBH vs TMDX Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, TMDX has a market cap of 3B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while TMDX trades at $87.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas TMDX's P/E ratio is 44.17. In terms of profitability, ZBH's ROE is +0.06%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, ZBH is more volatile compared to TMDX. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check TMDX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
ZBH vs AXGN Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, AXGN has a market cap of 2.7B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while AXGN trades at $49.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas AXGN's P/E ratio is 130.71. In terms of profitability, ZBH's ROE is +0.06%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, ZBH is more volatile compared to AXGN. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check AXGN's competition here
Butterfly Network, Inc. (NYSE: BFLY)
ZBH vs BFLY Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, BFLY has a market cap of 2.5B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while BFLY trades at $9.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas BFLY's P/E ratio is -39.35. In terms of profitability, ZBH's ROE is +0.06%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, ZBH is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check BFLY's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
ZBH vs UFPT Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, UFPT has a market cap of 2.5B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while UFPT trades at $322.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas UFPT's P/E ratio is 32.94. In terms of profitability, ZBH's ROE is +0.06%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, ZBH is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check UFPT's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
ZBH vs ESTA Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, ESTA has a market cap of 2.2B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while ESTA trades at $75.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas ESTA's P/E ratio is -59.98. In terms of profitability, ZBH's ROE is +0.06%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, ZBH is more volatile compared to ESTA. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check ESTA's competition here
NuVasive, Inc. (NASDAQ: NUVA)
ZBH vs NUVA Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas NUVA's P/E ratio is 75.00. In terms of profitability, ZBH's ROE is +0.06%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, ZBH is more volatile compared to NUVA. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check NUVA's competition here
Novocure Ltd (NASDAQ: NVCR)
ZBH vs NVCR Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, NVCR has a market cap of 2B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while NVCR trades at $17.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas NVCR's P/E ratio is -11.50. In terms of profitability, ZBH's ROE is +0.06%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, ZBH is more volatile compared to NVCR. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check NVCR's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
ZBH vs INSP Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, INSP has a market cap of 1.7B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while INSP trades at $58.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas INSP's P/E ratio is 25.67. In terms of profitability, ZBH's ROE is +0.06%, compared to INSP's ROE of +0.18%. Regarding short-term risk, ZBH is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check INSP's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
ZBH vs TNDM Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, TNDM has a market cap of 1.6B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while TNDM trades at $23.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas TNDM's P/E ratio is -21.31. In terms of profitability, ZBH's ROE is +0.06%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, ZBH is more volatile compared to TNDM. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check TNDM's competition here
CONMED Corporation (NYSE: CNMD)
ZBH vs CNMD Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while CNMD trades at $49.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas CNMD's P/E ratio is 10.89. In terms of profitability, ZBH's ROE is +0.06%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, ZBH is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check CNMD's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
ZBH vs ATEC Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while ATEC trades at $9.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas ATEC's P/E ratio is -160.50. In terms of profitability, ZBH's ROE is +0.06%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, ZBH is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check ATEC's competition here
Enovis Corporation (NYSE: ENOV)
ZBH vs ENOV Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, ENOV has a market cap of 1.4B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while ENOV trades at $24.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas ENOV's P/E ratio is 7.07. In terms of profitability, ZBH's ROE is +0.06%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, ZBH is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check ENOV's competition here
Artivion, Inc. (NYSE: AORT)
ZBH vs AORT Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, AORT has a market cap of 1.4B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while AORT trades at $28.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas AORT's P/E ratio is 47.72. In terms of profitability, ZBH's ROE is +0.06%, compared to AORT's ROE of -0.01%. Regarding short-term risk, ZBH is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check AORT's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
ZBH vs IART Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, IART has a market cap of 1.4B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while IART trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas IART's P/E ratio is 7.36. In terms of profitability, ZBH's ROE is +0.06%, compared to IART's ROE of -0.01%. Regarding short-term risk, ZBH is more volatile compared to IART. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check IART's competition here
Heska Corporation (NASDAQ: HSKA)
ZBH vs HSKA Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas HSKA's P/E ratio is -62.49. In terms of profitability, ZBH's ROE is +0.06%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, ZBH is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check HSKA's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
ZBH vs PRCT Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while PRCT trades at $21.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas PRCT's P/E ratio is -10.95. In terms of profitability, ZBH's ROE is +0.06%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, ZBH is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check PRCT's competition here
Avanos Medical, Inc. (NYSE: AVNS)
ZBH vs AVNS Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas AVNS's P/E ratio is 27.77. In terms of profitability, ZBH's ROE is +0.06%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, ZBH is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check AVNS's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
ZBH vs LMRI Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while LMRI trades at $11.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas LMRI's P/E ratio is -22.82. In terms of profitability, ZBH's ROE is +0.06%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, ZBH is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check LMRI's competition here
IRadimed Corporation (NASDAQ: IRMD)
ZBH vs IRMD Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while IRMD trades at $87.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas IRMD's P/E ratio is 43.92. In terms of profitability, ZBH's ROE is +0.06%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, ZBH is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check IRMD's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
ZBH vs SILK Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas SILK's P/E ratio is -18.96. In terms of profitability, ZBH's ROE is +0.06%, compared to SILK's ROE of -0.35%. Regarding short-term risk, ZBH is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check SILK's competition here
Paragon 28, Inc. (NYSE: FNA)
ZBH vs FNA Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas FNA's P/E ratio is -19.83. In terms of profitability, ZBH's ROE is +0.06%, compared to FNA's ROE of -0.35%. Regarding short-term risk, ZBH is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check FNA's competition here
Bioventus Inc. (NASDAQ: BVS)
ZBH vs BVS Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, BVS has a market cap of 942.7M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while BVS trades at $13.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas BVS's P/E ratio is 18.31. In terms of profitability, ZBH's ROE is +0.06%, compared to BVS's ROE of +0.28%. Regarding short-term risk, ZBH is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check BVS's competition here
InMode Ltd. (NASDAQ: INMD)
ZBH vs INMD Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, INMD has a market cap of 875.4M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while INMD trades at $15.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas INMD's P/E ratio is 10.58. In terms of profitability, ZBH's ROE is +0.06%, compared to INMD's ROE of +0.12%. Regarding short-term risk, ZBH is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check INMD's competition here
CeriBell, Inc. (NASDAQ: CBLL)
ZBH vs CBLL Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, CBLL has a market cap of 869.3M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while CBLL trades at $22.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas CBLL's P/E ratio is -14.06. In terms of profitability, ZBH's ROE is +0.06%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, ZBH is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check CBLL's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
ZBH vs AVR Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, AVR has a market cap of 862.4M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while AVR trades at $8.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas AVR's P/E ratio is -3.98. In terms of profitability, ZBH's ROE is +0.06%, compared to AVR's ROE of -1.24%. Regarding short-term risk, ZBH is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check AVR's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
ZBH vs CSII Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas CSII's P/E ratio is -20.83. In terms of profitability, ZBH's ROE is +0.06%, compared to CSII's ROE of -0.14%. Regarding short-term risk, ZBH is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check CSII's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
ZBH vs SIBN Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, SIBN has a market cap of 842.6M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while SIBN trades at $19.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas SIBN's P/E ratio is -55.88. In terms of profitability, ZBH's ROE is +0.06%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, ZBH is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check SIBN's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
ZBH vs AHCO Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, AHCO has a market cap of 785M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while AHCO trades at $5.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas AHCO's P/E ratio is 11.78. In terms of profitability, ZBH's ROE is +0.06%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, ZBH is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check AHCO's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
ZBH vs BBNX Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, BBNX has a market cap of 779.7M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while BBNX trades at $17.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas BBNX's P/E ratio is -11.48. In terms of profitability, ZBH's ROE is +0.06%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, ZBH is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check BBNX's competition here
Varex Imaging Corporation (NASDAQ: VREX)
ZBH vs VREX Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, VREX has a market cap of 776.7M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while VREX trades at $18.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas VREX's P/E ratio is 19.42. In terms of profitability, ZBH's ROE is +0.06%, compared to VREX's ROE of +0.05%. Regarding short-term risk, ZBH is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check VREX's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
ZBH vs SSII Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, SSII has a market cap of 738.5M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while SSII trades at $3.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas SSII's P/E ratio is -71.97. In terms of profitability, ZBH's ROE is +0.06%, compared to SSII's ROE of -0.23%. Regarding short-term risk, ZBH is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check SSII's competition here
BrainsWay Ltd. (NASDAQ: BWAY)
ZBH vs BWAY Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, BWAY has a market cap of 651.1M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while BWAY trades at $16.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas BWAY's P/E ratio is 42.17. In terms of profitability, ZBH's ROE is +0.06%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, ZBH is less volatile compared to BWAY. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check BWAY's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
ZBH vs KIDS Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, KIDS has a market cap of 638.5M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while KIDS trades at $24.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas KIDS's P/E ratio is -21.07. In terms of profitability, ZBH's ROE is +0.06%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, ZBH is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check KIDS's competition here
Surmodics, Inc. (NASDAQ: SRDX)
ZBH vs SRDX Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas SRDX's P/E ratio is -34.66. In terms of profitability, ZBH's ROE is +0.06%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, ZBH is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check SRDX's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
ZBH vs CTKB Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, CTKB has a market cap of 612.1M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while CTKB trades at $4.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas CTKB's P/E ratio is -25.11. In terms of profitability, ZBH's ROE is +0.06%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, ZBH is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check CTKB's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
ZBH vs DCTH Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, DCTH has a market cap of 590.7M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while DCTH trades at $17.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas DCTH's P/E ratio is 1711.00. In terms of profitability, ZBH's ROE is +0.06%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, ZBH is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check DCTH's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
ZBH vs APEN Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas APEN's P/E ratio is -9.43. In terms of profitability, ZBH's ROE is +0.06%, compared to APEN's ROE of -0.85%. Regarding short-term risk, ZBH is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check APEN's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
ZBH vs TCMD Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, TCMD has a market cap of 552.9M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while TCMD trades at $24.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas TCMD's P/E ratio is 27.85. In terms of profitability, ZBH's ROE is +0.06%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, ZBH is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check TCMD's competition here
Cerus Corporation (NASDAQ: CERS)
ZBH vs CERS Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, CERS has a market cap of 546.1M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while CERS trades at $2.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas CERS's P/E ratio is -54.09. In terms of profitability, ZBH's ROE is +0.06%, compared to CERS's ROE of -0.10%. Regarding short-term risk, ZBH is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check CERS's competition here
ZimVie Inc. (NASDAQ: ZIMV)
ZBH vs ZIMV Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, ZBH's ROE is +0.06%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, ZBH is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check ZIMV's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
ZBH vs NPCE Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, NPCE has a market cap of 496.4M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while NPCE trades at $14.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas NPCE's P/E ratio is -22.40. In terms of profitability, ZBH's ROE is +0.06%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, ZBH is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check NPCE's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
ZBH vs SGHT Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, SGHT has a market cap of 450.5M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while SGHT trades at $8.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas SGHT's P/E ratio is -14.79. In terms of profitability, ZBH's ROE is +0.06%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, ZBH is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check SGHT's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
ZBH vs CLPT Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, CLPT has a market cap of 446.8M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while CLPT trades at $15.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas CLPT's P/E ratio is -12.63. In terms of profitability, ZBH's ROE is +0.06%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, ZBH is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check CLPT's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
ZBH vs OFIX Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, OFIX has a market cap of 420.4M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while OFIX trades at $10.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas OFIX's P/E ratio is -13.59. In terms of profitability, ZBH's ROE is +0.06%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, ZBH is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check OFIX's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
ZBH vs CATX Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, CATX has a market cap of 373.5M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while CATX trades at $3.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas CATX's P/E ratio is -2.32. In terms of profitability, ZBH's ROE is +0.06%, compared to CATX's ROE of -0.42%. Regarding short-term risk, ZBH is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check CATX's competition here
Carlsmed, Inc. (NASDAQ: CARL)
ZBH vs CARL Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, CARL has a market cap of 373M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while CARL trades at $13.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas CARL's P/E ratio is -9.59. In terms of profitability, ZBH's ROE is +0.06%, compared to CARL's ROE of -0.38%. Regarding short-term risk, ZBH is less volatile compared to CARL. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check CARL's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
ZBH vs TLSI Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, TLSI has a market cap of 351.6M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while TLSI trades at $5.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas TLSI's P/E ratio is -3.40. In terms of profitability, ZBH's ROE is +0.06%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, ZBH is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check TLSI's competition here
Electromed, Inc. (AMEX: ELMD)
ZBH vs ELMD Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, ELMD has a market cap of 351.5M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while ELMD trades at $42.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas ELMD's P/E ratio is 36.28. In terms of profitability, ZBH's ROE is +0.06%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, ZBH is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check ELMD's competition here
Picard Medical, Inc. (AMEX: PMI)
ZBH vs PMI Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, PMI has a market cap of 349.2M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while PMI trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas PMI's P/E ratio is -2.83. In terms of profitability, ZBH's ROE is +0.06%, compared to PMI's ROE of +4.99%. Regarding short-term risk, ZBH is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check PMI's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
ZBH vs PACB Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, PACB has a market cap of 344.8M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while PACB trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas PACB's P/E ratio is -2.71. In terms of profitability, ZBH's ROE is +0.06%, compared to PACB's ROE of -49.62%. Regarding short-term risk, ZBH is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check PACB's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
ZBH vs SENS Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, SENS has a market cap of 331.4M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while SENS trades at $7.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas SENS's P/E ratio is -3.96. In terms of profitability, ZBH's ROE is +0.06%, compared to SENS's ROE of -1.66%. Regarding short-term risk, ZBH is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check SENS's competition here
CapsoVision, Inc. (NASDAQ: CV)
ZBH vs CV Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, CV has a market cap of 329.8M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while CV trades at $6.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas CV's P/E ratio is -2.64. In terms of profitability, ZBH's ROE is +0.06%, compared to CV's ROE of +1.27%. Regarding short-term risk, ZBH is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check CV's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
ZBH vs SMLR Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas SMLR's P/E ratio is 3.92. In terms of profitability, ZBH's ROE is +0.06%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, ZBH is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check SMLR's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
ZBH vs TMCI Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, TMCI has a market cap of 308.1M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while TMCI trades at $4.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas TMCI's P/E ratio is -5.05. In terms of profitability, ZBH's ROE is +0.06%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, ZBH is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check TMCI's competition here
Anika Therapeutics, Inc. (NASDAQ: ANIK)
ZBH vs ANIK Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, ANIK has a market cap of 294.8M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while ANIK trades at $22.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas ANIK's P/E ratio is 44.96. In terms of profitability, ZBH's ROE is +0.06%, compared to ANIK's ROE of -0.03%. Regarding short-term risk, ZBH is less volatile compared to ANIK. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check ANIK's competition here
RxSight, Inc. (NASDAQ: RXST)
ZBH vs RXST Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, RXST has a market cap of 292.3M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while RXST trades at $7.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas RXST's P/E ratio is -7.59. In terms of profitability, ZBH's ROE is +0.06%, compared to RXST's ROE of -0.17%. Regarding short-term risk, ZBH is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check RXST's competition here
Profound Medical Corp. (NASDAQ: PROF)
ZBH vs PROF Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, PROF has a market cap of 251.8M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while PROF trades at $6.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas PROF's P/E ratio is -5.59. In terms of profitability, ZBH's ROE is +0.06%, compared to PROF's ROE of -0.56%. Regarding short-term risk, ZBH is more volatile compared to PROF. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check PROF's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
ZBH vs MGRM Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas MGRM's P/E ratio is -12.00. In terms of profitability, ZBH's ROE is +0.06%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, ZBH is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check MGRM's competition here
Nevro Corp. (NYSE: NVRO)
ZBH vs NVRO Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas NVRO's P/E ratio is -1.91. In terms of profitability, ZBH's ROE is +0.06%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, ZBH is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check NVRO's competition here
Neuronetics, Inc. (NASDAQ: STIM)
ZBH vs STIM Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, STIM has a market cap of 223.4M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while STIM trades at $3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas STIM's P/E ratio is -5.94. In terms of profitability, ZBH's ROE is +0.06%, compared to STIM's ROE of -1.51%. Regarding short-term risk, ZBH is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check STIM's competition here
Avita Medical Inc. (NASDAQ: RCEL)
ZBH vs RCEL Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, RCEL has a market cap of 201.7M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while RCEL trades at $8.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas RCEL's P/E ratio is -5.17. In terms of profitability, ZBH's ROE is +0.06%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, ZBH is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check RCEL's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
ZBH vs BSGM Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas BSGM's P/E ratio is -5.81. In terms of profitability, ZBH's ROE is +0.06%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, ZBH is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check BSGM's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
ZBH vs LUCD Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, LUCD has a market cap of 187.8M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while LUCD trades at $0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas LUCD's P/E ratio is -2.66. In terms of profitability, ZBH's ROE is +0.06%, compared to LUCD's ROE of -3.70%. Regarding short-term risk, ZBH is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check LUCD's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
ZBH vs MDGS Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas MDGS's P/E ratio is -0.27. In terms of profitability, ZBH's ROE is +0.06%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, ZBH is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check MDGS's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
ZBH vs FOCL Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, FOCL has a market cap of 178M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while FOCL trades at $4.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas FOCL's P/E ratio is -5.80. In terms of profitability, ZBH's ROE is +0.06%, compared to FOCL's ROE of -1.38%. Regarding short-term risk, ZBH is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check FOCL's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
ZBH vs QIPT Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas QIPT's P/E ratio is -15.87. In terms of profitability, ZBH's ROE is +0.06%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, ZBH is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check QIPT's competition here
Inogen, Inc. (NASDAQ: INGN)
ZBH vs INGN Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, INGN has a market cap of 157.3M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while INGN trades at $5.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas INGN's P/E ratio is -6.38. In terms of profitability, ZBH's ROE is +0.06%, compared to INGN's ROE of -0.13%. Regarding short-term risk, ZBH is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check INGN's competition here
Quanterix Corporation (NASDAQ: QTRX)
ZBH vs QTRX Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, QTRX has a market cap of 138M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while QTRX trades at $2.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas QTRX's P/E ratio is -1.83. In terms of profitability, ZBH's ROE is +0.06%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, ZBH is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check QTRX's competition here
iCAD, Inc. (NASDAQ: ICAD)
ZBH vs ICAD Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas ICAD's P/E ratio is -20.37. In terms of profitability, ZBH's ROE is +0.06%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, ZBH is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check ICAD's competition here
Owlet, Inc. (NYSE: OWLT)
ZBH vs OWLT Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, OWLT has a market cap of 105.9M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while OWLT trades at $5.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas OWLT's P/E ratio is -41.79. In terms of profitability, ZBH's ROE is +0.06%, compared to OWLT's ROE of +11.36%. Regarding short-term risk, ZBH is less volatile compared to OWLT. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check OWLT's competition here
Solana Company (NASDAQ: HSDT)
ZBH vs HSDT Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, HSDT has a market cap of 101.6M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while HSDT trades at $1.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas HSDT's P/E ratio is -0.02. In terms of profitability, ZBH's ROE is +0.06%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, ZBH is more volatile compared to HSDT. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check HSDT's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
ZBH vs HJLI Comparison August 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.9B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, ZBH is priced at $97.89 on the NYSE, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.54, whereas HJLI's P/E ratio is N/A. In terms of profitability, ZBH's ROE is +0.06%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, ZBH is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check HJLI's competition here